Du är här

2017-06-07

AstraZeneca: AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig

AstraZeneca today announced that it has entered an agreement with
Grünenthal for the global rights to Zomig (zolmitriptan) outside
Japan. Zomig is indicated for the acute treatment of migraines and
cluster headaches, an area of medicine outside AstraZeneca's
strategic focus.

Grünenthal will pay AstraZeneca $200 million upon completion.
AstraZeneca will also receive up to an additional $102 million in
future milestone payments. Grünenthal will acquire the rights to
Zomig in all markets outside Japan, including the US, where the
rights were previously licensed to Impax Pharmaceuticals (Impax).
Impax will continue to market Zomig in the US. AstraZeneca will
continue to manufacture and supply the medicine to Grünenthal during
a transition period.

Mark Mallon, Executive Vice President, Global Product & Portfolio
Strategy at AstraZeneca said: "Grünenthal is an established partner
with expertise in the treatment of pain. It is well placed to ensure
patients continue to benefit from Zomig, and to extend the commercial
potential of the medicine through its dedicated salesforce."

Gabriel Baertschi, CEO of Grünenthal said: "Migraine is a very
debilitating disease with more than 75 million people worldwide
suffering from attacks that can lead to sensitivity to light or
sound, to nausea or even vomiting. The acquisition of the
well-established Zomig products complements our existing pain
portfolio. Migraine has been one of the very few main pain
indications we haven't yet been able to offer a solution for. This is
an important step to reach our ambition to become a €2 billion
company by 2022. It will also support our efforts to bring four to
five innovative products to market in the same timeframe."

- ENDS -

NOTES TO EDITORS

Financial considerations

In 2016, revenues from Zomig outside Japan were $96 million, including
Product Sales and Externalisation Revenue. The transaction is
expected to complete in the second quarter of 2017, subject to
customary closing conditions and regulatory clearances. The net
consideration from the agreement will be reported as Other Operating
Income in the Company's financial statements. The agreement does not
impact the Company's financial guidance for 2017.

About Zomig

Zomig (zolmitriptan) is indicated for the acute treatment of migraine,
and for the acute treatment of cluster headache in the EU. Zomig is
available in three formulations: An oral tablet, orally dispersible
tablet and nasal spray.

About Grünenthal

The Grünenthal Group is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a €2 billion
company. We are a fully integrated research & development company
with a long track record of bringing innovative pain treatments and
state-of-the-art technologies to patients. By sustainably investing
in our R&D above the industrial average, we are strongly committed to
innovation.

Grünenthal is an independent, family-owned company headquartered in
Aachen, Germany. We are present in 32 countries with affiliates in
Europe, Latin America and the US. Our products are sold in more than
155 countries and approx. 5,500 employees are working for the
Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of
approx. €1.4 bn. More information: www.grunenthal.com. Follow us on
LinkedIn: @GrunenthalGroup

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca
operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677

Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-enters-agreement-wit...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.